Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Global revenue of Amgen's Enbrel by region from 2011 to 2018
(in million U.S. dollars)
Amgen - revenue from Enbrel worldwide by region 2011-2018
This statistic displays the revenue that Amgen received through Enbrel worldwide by region from 2011 to 2018, in million U.S. dollars. In 2012, Enbrel generated almost four billion U.S. dollars of revenue in the United States alone. Enbrel is a biopharmaceutical product that is used to treat autoimmune diseases. It is marketed as a powder or a pre-mixed liquid. Previously, Enbrel was promoted by both Amgen and Pfizer in the United States and Canada. Since November 2016, the FDA approved the expanded use of Enbrel as a drug to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.
Global revenue of Amgen's Enbrel by region from 2011 to 2018
(in million U.S. dollars)
U.S. CanadaTotal
----
----
----
----
----
----
----
----
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

February 2019

Region

Worldwide

Survey time period

2011 to 2018

Amgen - revenue from Enbrel worldwide by region 2011-2018
This statistic displays the revenue that Amgen received through Enbrel worldwide by region from 2011 to 2018, in million U.S. dollars. In 2012, Enbrel generated almost four billion U.S. dollars of revenue in the United States alone. Enbrel is a biopharmaceutical product that is used to treat autoimmune diseases. It is marketed as a powder or a pre-mixed liquid. Previously, Enbrel was promoted by both Amgen and Pfizer in the United States and Canada. Since November 2016, the FDA approved the expanded use of Enbrel as a drug to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Pharmaceutical brands: Enbrel (Amgen/Pfizer)"
  • Overview
  • Drug prices and consumer behavior
  • Advertising expenditures
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.